Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27621835 | 0.96 | SLC6A4 (0.50) | SLC6A4ACHELMNAMAPK1SLC6A9 | |
| SCHEMBL468495 | 0.94 | SLC6A4 (0.52) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL27659201 | 0.92 | BCHE (0.47) | SLC6A4ACHESLC6A9 | |
| SCHEMBL20814664 | 0.90 | SLC6A4 (0.47) | SLC6A4ACHELMNAMAPK1SLC6A9 | |
| SCHEMBL30130509 | 0.90 | SLC6A4 (0.56) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL3408176 | 0.90 | SLC6A4 (0.56) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL21065413 | 0.90 | SLC6A4 (0.47) | SLC6A4ACHELMNAMAPK1 | |
| SCHEMBL21065408 | 0.90 | SLC6A4 (0.45) | SLC6A4ACHELMNAMAPK1SLC6A9 | |
| SCHEMBL27621832 | 0.90 | SLC6A4 (0.47) | SLC6A4ACHE | |
| SCHEMBL20814665 | 0.87 | SLC6A9 (0.45) | SLC6A4ACHELMNAMAPK1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1867358-A | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | LUNDBECK & CO AS H (DK) | 2006-11-22 | — | — | CN | claimed |
| EP-3006024-B1 | BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-03-20 | — | — | EP | disclosed |
| CN-1867358-A | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | LUNDBECK & CO AS H (DK) | 2006-11-22 | — | — | CN | disclosed |